Stephen T Worland E Ffector Therapeutics, Inc. (EFTR) insider trading activity

Stephen T Worland is Chief Executive Officer of eFFECTOR Therapeutics, Inc.. Currently has a direct ownership of 12,494 shares of EFTR, which is worth approximately $0. The most recent transaction as insider was on May 15, 2024, when has been sold 1,806 shares (Common Stock) at a price of $1.68 per share, resulting in proceeds of $3,034. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 12.5K

0% 3M change

95.22% 12M change

Total Value Held $0

STEPHEN T WORLAND Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 15 2024	BUY Grant, award, or other acquisition	$3,034 $1.68 p/Share	1,806 Added 12.63%	12,494 Common Stock
Nov 15 2023	BUY Grant, award, or other acquisition	$2,989 $0.5 p/Share	5,979 Added 2.19%	267,204 Common Stock
Aug 11 2023	BUY Exercise of conversion of derivative security	$17,575 $0.52 p/Share	33,799 Added 11.46%	261,225 Common Stock
May 15 2023	BUY Grant, award, or other acquisition	$2,944 $0.46 p/Share	6,401 Added 2.74%	227,426 Common Stock
Nov 15 2022	BUY Grant, award, or other acquisition	$2,842 $0.47 p/Share	6,047 Added 2.66%	221,025 Common Stock
Jun 07 2022	BUY Open market or private purchase	$27,400 $1.37 p/Share	20,000 Added 8.51%	214,978 Common Stock
May 13 2022	BUY Grant, award, or other acquisition	$2,811 $1.53 p/Share	1,837 Added 0.93%	194,978 Common Stock
Aug 25 2021	BUY Grant, award, or other acquisition	-	193,141 Added 20.36%	755,480 Common Stock

Also insider at

TCON

Tracon Pharmaceuticals, Inc. Healthcare

Director

STW